Azbil BioVigilant, Inc., inventors of Instantaneous Microbial Detection, recently announced that, for a third and final time, the Examiner for the US Patent and Trademark Office (USPTO) has issued a decision rejecting TSI’s latest arguments in the reexamination of U.S. Patent No. 6,831,279. Specifically, on December 19, 2013, the USPTO found that all claims of TSI’s patent are unpatentable. As is customary, the Office has issued a Right of Appeal Notice (RAN) allowing 30 days in which TSI may appeal the Examiner’s final decision to the Patent Trial and Appeal Board.
Representing Azbil BioVigilant in its patent litigation is Amster, Rothstein & Ebenstein LLP.
About Azbil BioVigilant
With headquarters in Tucson, Arizona, Azbil BioVigilant invented instantaneous microbial detection technology to address environmental monitoring needs in the pharmaceutical, biotechnology, healthcare, and environmental applications. Azbil BioVigilant’s IMD systems detect - instantaneously and in real-time - particle count, size, and biological status. Unlike other rapid microbial methods, Azbil BioVigilant’s optically-based systems require no staining, no reagents, no waiting period, and little human intervention. The company holds 19 patents with an additional 37 applications pending. Azbil BioVigilant’s parent company is Azbil Corporation of the azbil Group, part of the TOPIX Mid400 traded on the Tokyo Stock Exchange. For more information, visit www.biovigilant.com.
About azbil Group
The azbil Group consists of Azbil Corporation and its affiliate and subsidiary companies. The azbil Group has operations in 18 countries worldwide and more than 9,500 employees. For more information, visit www.azbil.com.
SOURCE: Azbil North America – Biovigilant Division